IL-15 and type I interferon are required for activation of tumoricidal NK cells by virus-infected dendritic cells

Cancer Research

Volumn 71, Issue 7, 2011, Pages 2497-2506

  Boudreau, Jeanette E ^a   Stephenson, Kyle B ^a   Wang, Fuan ^a   Ashkar, Ali A ^a   Mossman, Karen L ^a   Lenz, Laurel L ^b   Rosenthal, Kenneth L ^a   Bramson, Jonathan L ^a   Lichty, Brian D ^a   Wan, Yonghong ^a  

^a MCMASTER UNIVERSITY   (Canada)

^b DEPARTMENT OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERFERON; INTERLEUKIN 15; LIGAND; TOLL LIKE RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOCRINE EFFECT; CELL MATURATION; CELL PROTECTION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DENDRITIC CELL; FEMALE; LUNG TUMOR; LYMPHOCYTE ACTIVATION; MOUSE; NATURAL KILLER CELL; NONHUMAN; PARACRINE SIGNALING; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR GROWTH; VESICULAR STOMATITIS VIRUS; VIRUS INFECTION; VIRUS MUTANT;

ANIMALS; CANCER VACCINES; DENDRITIC CELLS; FEMALE; IMMUNOTHERAPY, ADOPTIVE; INTERFERON REGULATORY FACTOR-3; INTERFERON TYPE I; INTERLEUKIN-15; KILLER CELLS, NATURAL; LIGANDS; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; SIGNAL TRANSDUCTION; TOLL-LIKE RECEPTORS; VESICULOVIRUS;

EID: 79953321611     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-10-3025     Document Type: Article

References (50)

1. Gilboa E. DC-based cancer vaccines. J Clin Invest 2007;117:1195-203. (Pubitemid 46718404)
2. Ilett EJ, Prestwich RJ, Melcher AA. The evolving role of dendritic cells in cancer therapy. Expert Opin Biol Ther 2010;10:369-79.
3. Nakai N, Hartmann G, Kishimoto S, Katoh N. Dendritic cell vaccination in human melanoma: relationships between clinical effects and vaccine parameters. Pigment Cell Melanoma Res 2010;23:607-19.
4. Osada T, Clay T, Hobeika A, Lyerly HK, Morse MA. NK cell activation by dendritic cell vaccine: a mechanism of action for clinical activity. Cancer Immunol Immunother 2006;55:1122-31. (Pubitemid 43800727)
5. Viaud S, Terme M, Flament C, Taieb J, André F, Novault S, et al. Dendritic cell-derived exosomes promote natural killer cell activation and proliferation: a role for NKG2D ligands and IL-15Ralpha. PLoS ONE 2009;4:e4942.
6. Di Nicola M, Zappasodi R, Carlo-Stella C, Mortarini R, Pupa SM, Magni M, et al. Vaccination with autologous tumor-loaded dendritic cells induces clinical and immunologic responses in indolent B-cell lymphoma patients with relapsed and measurable disease: a pilot study. Blood 2009;113:18-27.
7. Boudreau JE, Bridle BW, Stephenson KB, Jenkins KM, Brunellière J, Bramson JL, et al. Recombinant vesicular stomatitis virus transduction of dendritic cells enhances their ability to prime innate and adaptive antitumor immunity. Mol Ther 2009;17:1465-72.
8. Rivoltini L, Carrabba M, Huber V, Castelli C, Novellino L, Dalerba P, et al. Immunity to cancer: attack and escape in T lymphocyte-tumor cell interaction. Immunol Rev 2002;188:97-113. (Pubitemid 35398868)
9. Zitvogel L. Dendritic and natural killer cells cooperate in the control/ switch of innate immunity. J Exp Med 2002;195:F9-14.
10. Gasser S, Raulet D. The DNA damage response, immunity and cancer. Semin Cancer Biol 2006;16:344-47. (Pubitemid 44311502)
11. Takeda K, Smyth MJ, Cretney E, Hayakawa Y, Kayagaki N, Yagita H, et al. Critical role for tumor necrosis factor-related apoptosis-inducing ligand in immune surveillance against tumor development. J Exp Med 2002;195:161-69. (Pubitemid 34461260)
12. Karimi K, Boudreau JE, Fraser K, Liu H, Delanghe J, Gauldie J, et al. Enhanced antitumor immunity elicited by dendritic cell vaccines is a result of their ability to engage both CTL and IFN gamma-producing NK cells. Mol Ther 2008;16:411-18. (Pubitemid 351168051)
13. Van Den Broek, Daschbach E, Thomas EK, Andringa G, Berzofsky JA. Dendritic cell-induced activation of adaptive and innate antitumor immunity. J Immunol 2003;171:5842-52. (Pubitemid 37467201)
14. Brandau S, Riemensberger J, Jacobsen M, Kemp D, Zhao W, Zhao X, et al. NK cells are essential for effective BCG immunotherapy. Int J Cancer 2001;92:697-702. (Pubitemid 32385713)
15. Grzywacz B, Miller JS, Verneris MR. Use of natural killer cells as immunotherapy for leukaemia. Best Pract Res Clin Haematol 2008;21:467-83.
16. Degli-Esposti M, Smyth MJ. Close encounters of different kinds: dendritic cells and NK cells take centre stage. Nat Rev Immunol 2005;5:112-24. (Pubitemid 40208901)
17. Witham T, Villa L, Yang T, Pollack IF, Okada H, Robbins PD, et al. Expression of a soluble transforming growth factor-β (TGFβ) receptor reduces tumorigenicity by regulating natural killer (NK) cell activity against 9L gliosarcoma in vivo. J Neurooncol 2003;64:63-69. (Pubitemid 36992461)
18. Ashiru O, Boutet P, Fernandez-Messina L, Agüera-González S, Skepper JN, Valés-Gómez M, et al. Natural killer cell cytotoxicity is suppressed by exposure to the human NKG2D ligand MICA*008 that is shed by tumor cells in exosomes. Cancer Res 2010;70:481-89.
19. Smyth MJ, Teng MW, Swann J, Kyparissoudis K, Godfrey DI, Hayakawa Y. CD4+CD25+ T regulatory cells suppress NK cell-mediated immunotherapy of cancer. J Immunol 2006;176:1582-7. (Pubitemid 43134302)
20. Liu C, Yu S, Zinn K, Wang J, Zhang L, Jia Y, et al. Murine mammary carcinoma exosomes promote tumor growth by suppression of NK cell function. J Immunol 2006;176:1375-85. (Pubitemid 43134279)
21. Stojdl DF, Lichty BD, tenOever BR, Paterson JM, Power AT, Knowles S, et al. VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents. Cancer Cell 2003;4:263-75.
22. Boudreau J, Koshy S, Cummings D, Wan Y. Culture of myeloid dendritic cells from bone marrow precursors. J Vis Exp 2008;17.
23. Ribas A, Vo D, Weeks D, Comin-Anduix B, Schumacher LY, Garban HJ, et al. Broad antitumor protection by dendritic cells administered to CD8alpha knock out mice. Cancer Immunol Immunother 2006;55:663-71.
24. Ahmed M, Brzoza KL, Hiltbold EM. Matrix protein mutant of vesicular stomatitis virus stimulates maturation of myeloid dendritic cells. J Virol 2006;80:2194-205. (Pubitemid 43271526)
25. Georgel P, Jiang Z, Kunz S, Janssen E, Mols J, Hoebe K, et al. Vesicular stomatitis virus glycoprotein G activates a specific antiviral toll-like receptor 4-dependent pathway. Virology 2007;362:304-13. (Pubitemid 46678142)
26. Coccia EM. IFN regulation and functions in myeloid dendritic cells. Cytokine Growth Factor Rev 2008;19:21-32. (Pubitemid 351200061)
27. Mortier E, Woo T, Advincula R, Gozalo S, Ma A. IL-15Rα chaperones IL-15 to stable dendritic cell membrane complexes that activate NK cells via trans presentation. J Exp Med 2008;205:1213-25. (Pubitemid 351679694)
28. Lucas M, Schachterle W, Oberle K, Aichele P, Diefenbach A. Dendritic cells prime natural killer cells by trans-presenting interleukin 15. Immunity 2007;26:503-17. (Pubitemid 46602996)
29. Kim A, Noh YW, Kim KD, Jang YS, Choe YK, Lim JS. Activated natural killer cell-mediated immunity is required for the inhibition of tumor metastasis by dendritic cell vaccination. Exp Mol Med 2004;36:428-43. (Pubitemid 39556419)
30. Adam C, King S, Allgeier T, Braumüller H, Lüking C, Mysliwietz J, et al. DC-NK cell cross talk as a novel CD4+ T-cell-independent pathway for antitumor CTL induction. Blood 2005;106:338-44. (Pubitemid 40967210)
31. Cooper MA, Elliott JM, Keyel PA, Yang L, Carrero JA, Yokoyama WM. Cytokine-induced memory-like natural killer cells. Proc Natl Acad Sci USA 2009;106:1915-19.
32. Komaru A, Ueda Y, Furuya A, Tanaka S, Yoshida K, Kato T, et al. Sustained and NK/CD4+ T cell-dependent efficient prevention of lung metastasis induced by dendritic cells harboring recombinant sendai virus. J Immunol 2009;138:4211-19.
33. Shimizu K, Fujii S. DC therapy induces long-term NK reactivity to tumors via host DC. Eur J Immunol 2009;39:457-68.
34. Honda K, Taniguchi T. IRFs: Master regulators of signalling by toll-like receptors and cytosolic pattern-recognition receptors. Nat Rev Immunol 2006;6:644-58. (Pubitemid 44298214)
35. Gutterman JU. Cytokine therapeutics: Lessons from interferon alpha. Proc Natl Acad Sci USA 1994;91:1198-205. (Pubitemid 24058977)
36. Dinney CP, Bielenberg DR, Perrotte P, Reich R, Eve BY, Bucana CD, et al. Inhibition of basic fibroblast growth factor expression, angiogenesis, and growth of human bladder carcinoma in mice by systemic interferon-alpha administration. Cancer Res 1998;58:808-14. (Pubitemid 28099496)
37. Ishii S, Hiroishi K, Eguchi J, Hiraide A, Imawari M. Dendritic cell therapy with interferon-alpha synergistically suppresses outgrowth of established tumors in a murine colorectal cancer model. Gene Ther 2006;13:78-87. (Pubitemid 41823854)
38. Bracci L, Proietti E, Belardelli F. IFN-alpha and novel strategies of combination therapy for cancer. Ann N Y Acad Sci 2007;1112:256-68. (Pubitemid 47598668)
39. Sikora A, Jaffarzad N, Hailemichael Y, Gelbard A, Stonier SW, Schluns KS, et al. IFN-alpha enhances peptide vaccine-induced CD8+ T cell numbers, effector function, and antitumor activity. J Immunol 2009; 182:7398-407.
40. Tough D. Type I interferon as a link between innate and adaptive immunity through dendritic cell stimulation. Leuk Lymphoma 2004;45:257-64. (Pubitemid 38181426)
41. Vilcek J. Fifty years of interferon research: aiming at a moving target. Immunity 2006;25:343-48. (Pubitemid 44354219)
42. Wongthida P, Diaz RM, Galivo F, Kottke T, Thompson J, Pulido J, et al. Type III IFN interleukin-28 mediates the antitumor efficacy of oncolytic virus VSV in immune-competent mouse models of cancer. Cancer Res 2010;70:4539-49.
43. Kaido T, Bandu MT, Maury C, Ferrantini M, Belardelli F, Gresser I. IFN-alpha 1 gene transfection completely abolishes the tumorigenicity of murine B16 melanoma cells in allogeneic DBA/2 mice and decreases their tumorigenicity in syngeneic C57BL/6 mice. Int J Cancer 1995;60:221-29.
44. Huntington N, Legrand N, Alves N, Jaron B, Weijer K, Plet A, et al. IL- 15 trans-presentation promotes human NK cell development and differentiation in vivo. J Exp Med 2009;206:25-34.
45. Pek EA, Chan T, Reid S, Ashkar AA. Characterization and IL-15 dependence of NK cells in humanized mice. Immunobiology 2011;216:218-24.
46. Nguyen KB, Salazar-Mather T, Dalod MY, Van Deusen JB, Wei XQ, Liew FY, et al. Coordinated and distinct roles for IFN-alpha beta, IL-12, and IL-15 regulation of NK cell responses to viral infection. J Immunol 2002;169:4279-87. (Pubitemid 35178200)
47. Sharif-Askari E, Fawaz LM, Tran P, Ahmad A, Menezes J. Interleukin 15-mediated induction of cytotoxic effector cells capable of eliminating epstein-barr virus-transformed/immortalized lymphocytes in culture. J Natl Cancer Inst 2001;93:1724-32. (Pubitemid 33130261)
48. Vujanovic L, Szymkowski D, Alber S, Watkins S, Vujanovic N, Butterfield L. Virally infected and matured human dendritic cells activate natural killer cells via cooperative activity of plasma membrane-bound TNF and IL-15. Blood 2010;116:575-83.
49. Ashkar A, Rosenthal K. Interleukin-15 and natural killer and NKT cells play a critical role in innate protection against genital herpes simplex virus type 2 infection. J Virol 2003;77:10168-71. (Pubitemid 37122101)
50. Sloan JM, Kershaw MH, Touloukian CE, Lapointe R, Robbins PF, Restifo NP, et al. MHC class I and class II presentation of tumor antigen in retrovirally and adenovirally transduced dendritic cells. Cancer Gene Ther 2002;9:946-50. (Pubitemid 35278567)